[HTML][HTML] The advances and challenges of NK cell-based cancer immunotherapy
S Kang, X Gao, L Zhang, E Yang, Y Li, L Yu - Current Oncology, 2021 - mdpi.com
Natural killer (NK) cells can be widely applied for cancer immunotherapy due to their ability
to lyse tumor targets without prior sensitization or human leukocyte antigens-matching …
to lyse tumor targets without prior sensitization or human leukocyte antigens-matching …
The Advances and Challenges of NK Cell-Based Cancer Immunotherapy
S Kang, X Gao, L Zhang, E Yang, Y Li, L Yu - Current Oncology, 2021 - cir.nii.ac.jp
抄録< jats: p> Natural killer (NK) cells can be widely applied for cancer immunotherapy due
to their ability to lyse tumor targets without prior sensitization or human leukocyte antigens …
to their ability to lyse tumor targets without prior sensitization or human leukocyte antigens …
The Advances and Challenges of NK Cell-Based Cancer Immunotherapy.
S Kang, X Gao, L Zhang, E Yang, Y Li… - Current …, 2021 - search.ebscohost.com
Natural killer (NK) cells can be widely applied for cancer immunotherapy due to their ability
to lyse tumor targets without prior sensitization or human leukocyte antigens-matching …
to lyse tumor targets without prior sensitization or human leukocyte antigens-matching …
The Advances and Challenges of NK Cell-Based Cancer Immunotherapy
S Kang, X Gao, L Zhang, E Yang… - Current oncology …, 2021 - pubmed.ncbi.nlm.nih.gov
Natural killer (NK) cells can be widely applied for cancer immunotherapy due to their ability
to lyse tumor targets without prior sensitization or human leukocyte antigens-matching …
to lyse tumor targets without prior sensitization or human leukocyte antigens-matching …
[PDF][PDF] The Advances and Challenges of NK Cell-Based Cancer Immunotherapy
S Kang, X Gao, L Zhang, E Yang, Y Li, L Yu - Curr. Oncol - pdfs.semanticscholar.org
Natural killer (NK) cells can be widely applied for cancer immunotherapy due to their ability
to lyse tumor targets without prior sensitization or human leukocyte antigens-matching …
to lyse tumor targets without prior sensitization or human leukocyte antigens-matching …
[HTML][HTML] The Advances and Challenges of NK Cell-Based Cancer Immunotherapy
S Kang, X Gao, L Zhang, E Yang, Y Li, L Yu - Current Oncology, 2021 - ncbi.nlm.nih.gov
Natural killer (NK) cells can be widely applied for cancer immunotherapy due to their ability
to lyse tumor targets without prior sensitization or human leukocyte antigens-matching …
to lyse tumor targets without prior sensitization or human leukocyte antigens-matching …
[PDF][PDF] The Advances and Challenges of NK Cell-Based Cancer Immunotherapy
S Kang, X Gao, L Zhang, E Yang, Y Li, L Yu - Curr. Oncol - researchgate.net
Natural killer (NK) cells can be widely applied for cancer immunotherapy due to their ability
to lyse tumor targets without prior sensitization or human leukocyte antigens-matching …
to lyse tumor targets without prior sensitization or human leukocyte antigens-matching …
The Advances and Challenges of NK Cell-Based Cancer Immunotherapy.
S Kang, X Gao, L Zhang, E Yang, Y Li… - … Oncology (Toronto, Ont.), 2021 - europepmc.org
Natural killer (NK) cells can be widely applied for cancer immunotherapy due to their ability
to lyse tumor targets without prior sensitization or human leukocyte antigens-matching …
to lyse tumor targets without prior sensitization or human leukocyte antigens-matching …